Oncolytics Biotech, Inc.
1167 Kensington Crescent NW
Suite 210
Calgary,
AB T2N 1X7
Canada - Map
Phone: 403-670-7377
Fax: 403-283-0508
Website: http://www.oncolyticsbiotech.com
| Index Membership: | N/A | | Sector: | Healthcare | | Industry: | Biotechnology | | Full Time Employees: | N/A |
|
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada. Key Statistics
| |
| | Pay | Exercised | Dr. Bradley G. Thompson Ph.D.,
Exec. Chairman, Chief Exec. Officer and Pres | 571.00k | 0.00 | Mr. Kirk J. Look ,
Chief Financial Officer and Chief Financial Officer of Oncolytics Biotech (U.S.) Inc. | 44.00k | 0.00 | Dr. Matthew C. Coffey Ph.D.,
Chief Operating Officer and Director | 393.00k | 0.00 | Dr. George M. Gill M.D.,
Chief Safety Officer and Sr. VP of Clinical & Regulatory Affairs | 336.00k | 0.00 | Dr. Alan J. Tuchman M.D.,
66
Chief Medical Officer and Sr. VP of Clinical & Medical Devel. | 38.00k | 0.00 |
|
| | Amounts are as of 2012-12-30 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in CAD. |
|
0.04(1.41%) 2:06PM EDT